SMN

Beth Bacall Joins Salem Music Network

Retrieved on: 
Monday, April 29, 2024
TV and Radio, General Entertainment, Entertainment, Salem Media Group, Music, Radio, OTCQX, Salem Radio Network, Kevin, TCM, Media Group, Christian music, SMN, Multimedia, Broadcaster, Fish, Atmosphere, Growth

Salem Media Group, Inc. (OTCQX: SALM) announced today that Beth Bacall has joined the Salem Music Network (“SMN”) based in Nashville, TN.

Key Points: 
  • Salem Media Group, Inc. (OTCQX: SALM) announced today that Beth Bacall has joined the Salem Music Network (“SMN”) based in Nashville, TN.
  • The Beth Bacall Show content is available for stations to air in any daypart by ftp download.
  • She has won the Christian Music Broadcaster’s (“CMB”) Industry Achievement Award for outstanding and long-term contributions to the growth of Christian music radio.
  • Salem Music Network’s FTP talent includes: The Kevin and Taylor Show, Keep the Faith with Penny, The Scott and Sam Show, and The Beth Bacall Show.

Orphan designation: branaplam Treatment of spinal muscular atrophy, 16/04/2018 Withdrawn

Retrieved on: 
Thursday, April 18, 2024
Eurostat, Diagnosis, Civil service commission, SMN, Brain, Atrophy, Gene, Weakness, Spinal muscular atrophy, Survival, Medicine, Disease, Paralysis, Novartis, Patient, Committee, Knowledge, Ventilation, Regulation, Brain cell, EMA, IRIS, Mouth, European, COMP, Spinal cord, Sponsor, European Commission, Spine, Safety, SMN1, Marketing, SMN2, Pharmaceutical industry

Orphan designation: branaplam Treatment of spinal muscular atrophy, 16/04/2018 Withdrawn

Key Points: 


Orphan designation: branaplam Treatment of spinal muscular atrophy, 16/04/2018 Withdrawn

Scholar Rock Reports Full Year 2023 Financial Results and Highlights Business Progress

Retrieved on: 
Tuesday, March 19, 2024
Research, FDA, Clinical Trials, Cardiology, Biotechnology, Pharmaceutical, Health, Science, Oncology, Other Science, Overweight, SMN, Conference, Obesity, Keystone, MDA, Gilead Sciences, SAPPHIRE, SMA, Manuscript, Myostatin, Rock, Muscular dystrophy, Muscular Dystrophy Association, Trial of the century, Efficacy, Clinical trial, Therapy, Literature, Lunch, Pharmaceutical industry

“In 2023, Scholar Rock made significant progress across our industry-leading antimyostatin pipeline, and we are poised for a transformational year ahead.

Key Points: 
  • “In 2023, Scholar Rock made significant progress across our industry-leading antimyostatin pipeline, and we are poised for a transformational year ahead.
  • Scholar Rock remains on track to report topline data from the Phase 3 trial in the fourth quarter of 2024.
  • Scholar Rock also presented a literature review that describes the ongoing burden and significant unmet needs in SMA despite advancements in treatment.
  • Dr. Qatanani joined Scholar Rock in 2021 and has been leading all research functions since 2022 and driving Scholar Rock’s early-stage pipeline, including SRK-439.

Scholar Rock Provides Corporate Update and Highlights Priorities for 2024

Retrieved on: 
Thursday, January 4, 2024
Research, Neurology, Diabetes, Clinical Trials, Cardiology, Biotechnology, Managed Care, Pharmaceutical, Health, Science, Conference, Cure, IND, SAPPHIRE, Spinal muscular atrophy, Clinical trial, Obesity, Standard of care, Annual general meeting, Gongshi, Consequence, Myostatin, DRAGON, Webcast, MPH, Patient, Rock, SMN, SMA, Renal cell carcinoma, SITC, Pharmaceutical industry

Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy (SMA), cardiometabolic disorders, and other serious diseases where protein growth factors play a fundamental role, today provided recent corporate updates and highlighted upcoming priorities for 2024.

Key Points: 
  • Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy (SMA), cardiometabolic disorders, and other serious diseases where protein growth factors play a fundamental role, today provided recent corporate updates and highlighted upcoming priorities for 2024.
  • Planning to announce Phase 3 SAPPHIRE clinical trial topline data in 4Q 2024.
  • Scholar Rock management will highlight these updates in a corporate presentation at the 42nd Annual J.P. Morgan Healthcare Conference on Tuesday, January 9, 2024, at 1:30 p.m. PT (4:30 p.m.
  • A live webcast of the presentation may be accessed by visiting the Investors & Media section of the Scholar Rock website at http://investors.scholarrock.com .

Scholar Rock Reports Third Quarter 2023 Financial Results and Highlights Business Progress

Retrieved on: 
Tuesday, November 7, 2023
Science, Cardiology, Biotechnology, Research, Pharmaceutical, Oncology, Health, Clinical Trials, Gongshi, Myostatin, SMN, SAPPHIRE, IND, PIN, MPH, Obesity, Pembrolizumab, Maintenance, SITC, Rock, DRAGON, Clinical trial, Neoplasm, Webcast, Annual general meeting, ORR, Renal cell carcinoma, SMA, Patient, Pharmaceutical industry, Cryptocurrency

The Company announced that it completed enrollment in September 2023, with topline data expected in the fourth quarter of 2024.

Key Points: 
  • The Company announced that it completed enrollment in September 2023, with topline data expected in the fourth quarter of 2024.
  • Research and development expense was $30.3 million for the quarter ended September 30, 2023, compared to $33.4 million for the quarter ended September 30, 2022.
  • General and administrative expense was $13.3 million for the quarter ended September 30, 2023, compared to $10.5 million for the quarter ended September 30, 2022.
  • A live webcast of the conference call will be available on the Investors & Media section of the Scholar Rock website at http://investors.scholarrock.com .

Medical Properties Trust, Inc. Confirms Long-Term Strength, Stability and Performance of Business Model in Third Quarter Results

Retrieved on: 
Thursday, October 26, 2023
REIT, Hospitals, Health, Commercial Building & Real Estate, Construction & Property, Centene Corporation, PHP, SMN, United Kingdom, NYSE, Health care, International, Government, Regulation, MPT, Telephone, Disclosure, GAAP, Acquisition, Sold, Tenant, Priory, Circle Health, Genolier Swiss Medical Network SA, Growth, Medical Properties Trust, NFFO, Webcast, Regulation Fair Disclosure, Hospital, MPW, Running, Collection, Investment, Hyundai Doosan Infracore, Bed, Calendar, EBITDAR, CHF, Life insurance, Commercial property, Lease, Bank, Cryptocurrency

“Our business model remains strong and stable,” said Edward K. Aldag, Jr., Chairman, President and Chief Executive Officer.

Key Points: 
  • “Our business model remains strong and stable,” said Edward K. Aldag, Jr., Chairman, President and Chief Executive Officer.
  • As of September 30, 2023, MPT’s portfolio included 441 properties and approximately 44,000 licensed beds.
  • During the third quarter, Centene Corporation agreed to sell Circle Health (“Circle”) ($2 billion) to PureHealth at a value of roughly $1.2 billion.
  • Call participants are to ask the operator to be joined to the Medical Properties Trust, Inc. conference call upon dialing in.

Scholar Rock Announces Completion of Enrollment for the Phase 3 SAPPHIRE Trial

Retrieved on: 
Tuesday, September 19, 2023
Health, Genetics, Clinical Trials, General Health, Pharmaceutical, Biotechnology, SMN, SMA, Pediatrics, SAPPHIRE, Publication, Rock, Johns Hopkins University, Patient, Neurology, MPH, Poster, Safety, Fatigue, Pharmaceutical industry, Q4

Scholar Rock (NASDAQ: SRRK), a Phase 3 clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, announced today that it has completed enrollment of the SAPPHIRE Phase 3 trial evaluating the safety and efficacy of apitegromab in nonambulatory patients with Types 2 and 3 spinal muscular atrophy (SMA) who are receiving SMN therapy (either nusinersen or risdiplam).

Key Points: 
  • Scholar Rock (NASDAQ: SRRK), a Phase 3 clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, announced today that it has completed enrollment of the SAPPHIRE Phase 3 trial evaluating the safety and efficacy of apitegromab in nonambulatory patients with Types 2 and 3 spinal muscular atrophy (SMA) who are receiving SMN therapy (either nusinersen or risdiplam).
  • The company also announced that it plans to present encore data from its Phase 2 TOPAZ trial extension period evaluating patient outcomes in SMA after 36 months of treatment with apitegromab.
  • “Completing SAPPHIRE enrollment is a critical step on the path to bringing apitegromab, a potentially transformative therapy, to individuals living with SMA.
  • SAPPHIRE was designed to build on the positive TOPAZ results, and we look forward to reporting the topline results from this registrational study in Q4 next year,” said Jay Backstrom, M.D., MPH, President and Chief Executive Officer of Scholar Rock.

Muscular Dystrophy Association Announces Research Grants Totaling $8.4 Million

Retrieved on: 
Wednesday, September 13, 2023
Muscular dystrophy, Mir-126, Muscular Dystrophy Association, SMA, SMN, University, Duchenne muscular dystrophy, EDMD, DM, Grant, Doctor of Philosophy, Barrier, DM1, University of Zurich, Johns Hopkins School of Medicine, Columbia University Irving Medical Center, Tel Aviv University, Emery–Dreifuss muscular dystrophy, University of Iowa, Prognosis, Research, Mentorship, Charcot–Marie–Tooth disease, RNA, CMT, Duchenne, Facial muscles, Glycogen storage disease type II, Student, University of Rochester, Neuromuscular disease, DMD, Patient, Regents of the University of Michigan, Diagnosis, Growth, Regent, B cell, Health, MDA, FDA, Mobile app, ALS, Myotonic dystrophy, LGMD, Disease, Pharmaceutical industry, Medical device, Nursing, Exercise

New York, Sept. 13, 2023 (GLOBE NEWSWIRE) -- The Muscular Dystrophy Association (MDA) announced today the awarding of 37 new grants with a total funding commitment of $8.4 million toward neuromuscular disease research.

Key Points: 
  • New York, Sept. 13, 2023 (GLOBE NEWSWIRE) -- The Muscular Dystrophy Association (MDA) announced today the awarding of 37 new grants with a total funding commitment of $8.4 million toward neuromuscular disease research.
  • The newly funded projects aim to advance research discoveries and new therapy development in multiple areas including amyotrophic lateral sclerosis (ALS), Charcot-Marie-Tooth disease (CMT), Duchenne muscular dystrophy (DMD), Emery-Dreifuss muscular dystrophy (EDMD), limb-girdle muscular dystrophy (LGMD), spinal muscular atrophy (SMA), myotonic dystrophy (DM), and many more.
  • “The Muscular Dystrophy Association has consistently been a leader in advancing treatments for people living with muscular dystrophy, ALS and related neuromuscular diseases,” said Donald S. Wood, Ph.D., President and CEO, Muscular Dystrophy Association.
  • Internship recipients and mentors included:
    These are just a few of the many grants the Muscular Dystrophy Association has pledged to support.

Scholar Rock Reports Second Quarter 2023 Financial Results and Highlights Business Progress

Retrieved on: 
Wednesday, August 9, 2023
Biotechnology, Pharmaceutical, Health, SMN, SMA, Gongshi, Myostatin, Clinical trial, SAPPHIRE, Cure, Research, Part, Antibody, Rock, Patient, Standard of care, DRAGON, Safety, Pharmaceutical industry, Cryptocurrency

Scholar Rock (NASDAQ: SRRK), a Phase 3 clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today reported financial results and corporate updates for the second quarter ended June 30, 2023.

Key Points: 
  • Scholar Rock (NASDAQ: SRRK), a Phase 3 clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today reported financial results and corporate updates for the second quarter ended June 30, 2023.
  • Research and development expense was $26.9 million for the quarter ended June 30, 2023, compared to $32.1 million for the quarter ended June 30, 2022.
  • General and administrative expense was $12.2 million for the quarter ended June 30, 2023, compared to $11.1 million for the quarter ended June 30, 2022.
  • Our overall execution, along with our spend for the first six months of 2023, is aligned with our strategic plan,” said Ted Myles, Chief Operating Officer and Chief Financial Officer of Scholar Rock.

Four-Year Follow-Up Data for Genentech’s Evrysdi Show Continued Increase in Number of Children With a Severe Form of Spinal ​Muscular ​Atrophy (SMA)​ Able to Sit, Stand and Walk

Retrieved on: 
Friday, June 30, 2023
Biotechnology, Consumer, Health, Pharmaceutical, Children, SMN, SMA, Disease, PTC Therapeutics, SMN2, PTC, Aes, Roche, Cure, Medicine, ROG, RO, Bayley Scales of Infant Development, Walking, Patient, Infant, Ageing, Upper respiratory tract infection, Therapy, Pneumonia, Mouth, UCL Great Ormond Street Institute of Child Health, Birth control, Pharmaceutical industry, Genentech, Fever, Risdiplam

After four years of treatment with Evrysdi, many of the babies, now young children, continued to improve their ability to sit, stand and walk without support.

Key Points: 
  • After four years of treatment with Evrysdi, many of the babies, now young children, continued to improve their ability to sit, stand and walk without support.
  • All the Evrysdi-treated children who were alive at the time of the primary analysis were still alive at month 48.
  • Additionally, the majority of infants maintained their ability to feed by mouth and swallow up to month 48.
  • Genentech leads the clinical development of Evrysdi as part of a collaboration with the SMA Foundation and PTC Therapeutics.